Record sales and margin performance
Sales up 9% with core organic growth of 6%
Reported net income from continuing operations attributable to ESAB of $67 million and core adjusted EBITDA of.
Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, July 25, 2023 FTAI Infrastructure Inc. today reported financial results for the second quarter 2023. The Company’s consolidated comparative financial statements and key performance.
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights.